PartnerFacts
Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 7:28 AM ET

Sponsor Check › Issuer

OP

Omthera Pharmaceuticals, Inc.

Corporation · organized in Delaware · formed 2008 · New Jersey, NJ

$39Mreported sold (max)
13investors (max)
3offerings
4Form D filings
2009–2013filing years
0new, last 12 mo
Follow this issuerConnect me with this sponsorEmail me the full reportLook further ↓

Data last updated Oct 23, 2026, 5:45 PM ET · Latest filing by this issuer Feb 28, 2013 · Courts (RECAP) last checked: Oct 24, 2026, 2:11 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET

The short version

Omthera Pharmaceuticals, Inc. is a corporation organized in Delaware (formed 2008), based in New Jersey, NJ.

What this means A deal company is usually set up for one investment; its Form D is the notice it files after selling to investors.

It has filed 4 Form D filings (3 originals, 1 amendment) for 3 offerings between Nov 2009 and Feb 2013. The latest filing of each offering reports a combined $58.8M sold of an indefinite amount offered to 27 investors; industry as reported: pharmaceuticals; latest exemption Rule 506.

What this means A repeat filer — 3 separate raises over about 4 years. Amendments are routine updates (an ongoing raise must update its Form D at least once a year).

Key people as listed: Bernardus Machielse (executive officer), Christian Schade (executive officer), David Mott (director), George Horner (director), Gerald Wisler (executive officer and director) and 3 more.

What this means These are the people the company itself named as running or promoting it. Tap a name to see every other deal they are on.

Reported money out: $400K of proceeds to officers, directors or promoters (latest filing per offering). No sales-compensation recipients are listed.

What this means $400K of investor money was reported as going to the people running the deal — about 0.7% of what was sold. The form does not say what for (fees, salaries, buying something from them); ask. No broker was paid — the sponsor sold it directly to investors.

Activity: 0 new offerings in the last 12 months; latest amendment Jan 6, 2012; latest filing Feb 28, 2013.

What this means No new raise filed in the past year — this deal company may be done raising, or simply quiet.

Searched SEC Form ADV bulk data (registered + exempt reporting advisers) (24,962 records as of Oct 2, 2026, 8:00 AM ET) — nothing matched Omthera Pharmaceuticals, Inc..

Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY), property records (NYC, FL, IL and TX counties) — none found.

What this means Nothing turned up where we looked (4 sources). That does not prove there is nothing — it means none was found in those sources on that date.

We compared 4 public filings for Omthera Pharmaceuticals, Inc. and found 9 differences, 2 worth asking the sponsor about: Douglas Carr is no longer listed on the Jan 6, 2012 amendment; Michael Davidson is no longer listed on the Jan 6, 2012 amendment; and more below.

What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.

What the community is saying

Community search for Omthera Pharmaceuticals, Inc. has not run yet — it is joining a line of 22,409 names; searches run around the clock at the hosts' allowed rate. Searched so far: 628 names.

Community comments are quoted as written by their authors. Sources searched: BiggerPockets forums (via DuckDuckGo, Brave, Bing and BiggerPockets search) and Reddit (search feed + public archive).

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

None found in sources searched — federal courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:11 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: VA (crawled Oct 23, 2026)

What was searched

SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched Omthera Pharmaceuticals, Inc...

State securities regulators: Securities regulators searched (3,318 actions): AZ Corporation Commission Securities Division (411 actions, 2017–2026), CA DFPI (25 actions, 2007–2024; listing starts 2002 — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE DOJ Investor Protection Unit (257 actions, 1987–2026), TX State Securities Board (586 actions, 2006–2026), WA DFI (2,039 actions, 2001–2026) — last crawled Oct 23, 2026, 9:57 PM ET. No machine-readable public listing today for CO, FL, IA, IN, MN, NE, NJ, NY, OH, UT, VA (see docs/state-regulators.md).

3. Bankruptcies

None found in sources searched — federal bankruptcy courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:11 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

4. Differences between public sources

No comparisons published

What is compared

No public statement by this issuer has been collected yet, so there is nothing to compare. Sources compared: the sponsor's own website (known from the issuer's own filings — Form C issuer website, EDGAR company profile — an approved profile claim or Form ADV Item 1.I of its matched adviser) · SEC Form D · SEC Form ADV (IAPD) · Internet Archive · No website is on file for this issuer yet.

9 differences found between the filings for Omthera Pharmaceuticals, Inc. — 2 worth asking about (compared 4 filings on Oct 24, 2026)

Note · Nov 27, 2009

19% of the money raised went to insiders — Omthera Pharmaceuticals, Inc.

The Nov 27, 2009 Form D reports $2,158,333 sold and $400,000 of the proceeds used for payments to officers, directors or promoters (marked as an estimate). Issuer's note: "Proceeds will be used for operating expenses, including salaries.".

What this means The filing reports how much of the money raised was paid to insiders. Over 10% is high for most deals. Ask what it paid for.

Form D · Nov 27, 2009 ↗Omthera Pharmaceuticals, Inc. — PartnerFacts page ↗
Sources
Note · Feb 15, 2013 – Feb 28, 2013

No amendment in the last 12 months on an offering that may still be open — Omthera Pharmaceuticals, Inc. (latest filing Feb 28, 2013)

The latest filing for this offering is dated Feb 28, 2013 (first sale Feb 15, 2013). It reports $17,600,000 sold of an indefinite amount offered. No later amendment is in our index as of Oct 24, 2026.

What this means SEC rules expect a yearly amendment while an offering is still going. The raise may simply have ended — a Form D does not say when it closed. Ask the sponsor whether the offering closed, when, and at what amount.

Form D · Feb 28, 2013 ↗Omthera Pharmaceuticals, Inc. — PartnerFacts page ↗
Sources
Note · Feb 28, 2011 – Jan 6, 2012

No amendment in the last 12 months on an offering that may still be open — Omthera Pharmaceuticals, Inc. (latest filing Jan 6, 2012)

The latest filing for this offering is dated Jan 6, 2012 (first sale Feb 28, 2011). It reports $39,009,465 sold of $49,009,465 offered. No later amendment is in our index as of Oct 24, 2026.

What this means SEC rules expect a yearly amendment while an offering is still going. The raise may simply have ended — a Form D does not say when it closed. Ask the sponsor whether the offering closed, when, and at what amount.

Form D/A · Jan 6, 2012 ↗Omthera Pharmaceuticals, Inc. — PartnerFacts page ↗
Sources
Note · Nov 13, 2009 – Nov 27, 2009

No amendment in the last 12 months on an offering that may still be open — Omthera Pharmaceuticals, Inc. (latest filing Nov 27, 2009)

The latest filing for this offering is dated Nov 27, 2009 (first sale Nov 13, 2009). It reports $2,158,333 sold of an indefinite amount offered. No later amendment is in our index as of Oct 24, 2026.

What this means SEC rules expect a yearly amendment while an offering is still going. The raise may simply have ended — a Form D does not say when it closed. Ask the sponsor whether the offering closed, when, and at what amount.

Form D · Nov 27, 2009 ↗Omthera Pharmaceuticals, Inc. — PartnerFacts page ↗
Sources
Worth asking · Mar 15, 2011 – Jan 6, 2012

Douglas Carr is no longer listed on the Jan 6, 2012 amendment — Omthera Pharmaceuticals, Inc.

Douglas Carr appears on the Mar 15, 2011 Form D (executive officer) but not on the Jan 6, 2012 Form D/A for the same offering.

What this means People leave, and the issuer must list only current officers, directors and promoters. It is still worth asking why this person left and who replaced them.

Form D · Mar 15, 2011 ↗Form D/A · Jan 6, 2012 ↗Douglas Carr — PartnerFacts page ↗Omthera Pharmaceuticals, Inc. — PartnerFacts page ↗
Sources
Worth asking · Mar 15, 2011 – Jan 6, 2012

Michael Davidson is no longer listed on the Jan 6, 2012 amendment — Omthera Pharmaceuticals, Inc.

Michael Davidson appears on the Mar 15, 2011 Form D (executive officer) but not on the Jan 6, 2012 Form D/A for the same offering.

What this means People leave, and the issuer must list only current officers, directors and promoters. It is still worth asking why this person left and who replaced them.

Form D · Mar 15, 2011 ↗Form D/A · Jan 6, 2012 ↗Michael Davidson — PartnerFacts page ↗Omthera Pharmaceuticals, Inc. — PartnerFacts page ↗
Sources
Note · Mar 15, 2011 – Jan 6, 2012

Offering amount changed between filings — Omthera Pharmaceuticals, Inc.

The Mar 15, 2011 filing says $38,659,480 offered; the Jan 6, 2012 Form D/A says $49,009,465.

What this means The target raise changed. Raising the cap is common when a deal grows; ask whether the extra money has the same terms and use.

Form D (earlier) · Mar 15, 2011 ↗Form D/A (later) · Jan 6, 2012 ↗Omthera Pharmaceuticals, Inc. — PartnerFacts page ↗
Sources
Note · Mar 15, 2011 – Jan 6, 2012

Address moved from Bedminster, NJ to Princeton, NJ — Omthera Pharmaceuticals, Inc.

The people listed on the Mar 15, 2011 filing give Bedminster, NJ; on the Jan 6, 2012 filing they give Princeton, NJ.

What this means Businesses move; this just shows the two places and dates. If you were told one city and the forms say another, ask which is current.

Form D · Mar 15, 2011 ↗Form D/A · Jan 6, 2012 ↗Omthera Pharmaceuticals, Inc. — PartnerFacts page ↗
Sources
Note · Nov 27, 2009 – Mar 15, 2011

Address moved from Gladstone, NJ to Bedminster, NJ — Omthera Pharmaceuticals, Inc.

The people listed on the Nov 27, 2009 filing give Gladstone, NJ; on the Mar 15, 2011 filing they give Bedminster, NJ.

What this means Businesses move; this just shows the two places and dates. If you were told one city and the forms say another, ask which is current.

Form D · Nov 27, 2009 ↗Form D · Mar 15, 2011 ↗Omthera Pharmaceuticals, Inc. — PartnerFacts page ↗
Sources
What is compared

What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. As of Oct 24, 2026.

5. Money to insiders

0 of 3 offerings report sales commissions; 0 report finder's fees; 1 reports proceeds to related persons totalling $400,000. (includes amounts the issuer reported as estimates)

Offering (latest filing)Sales commissionsFinder's feesTo insidersPaid to sell itSource
Feb 28, 2013 D
File 021-192546
$0$0$0None listed on this filingEDGAR ↗
Jan 6, 2012 D/A
File 021-156702
$0$0$0
Some of the funds will be used as working capital and therefore to pay normal business expenses, such as salaries of officers.
None listed on this filingEDGAR ↗
Nov 27, 2009 D
File 021-136458
$0$0$400,000 (est.)
Proceeds will be used for operating expenses, including salaries.
None listed on this filingEDGAR ↗
How this is counted

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Property records 0 documents · 0 ownership records · last checked Oct 24, 2026, 7:27 AM ET · NYC and Cook County lookup still to run

0 recorded documents and 0 ownership records matched to Omthera Pharmaceuticals, Inc. in the sources searched.

Not found in sources searched as of Oct 24, 2026, 7:27 AM ET: Hillsborough County FL Clerk of Court Official Records daily index (publicrec.hillsclerk.com D/P/M files), 2 daily files (Oct 14, 2026 to Oct 15, 2026) — loaded Oct 23, 2026, 8:59 PM ET; Harris County TX (HCAD ownership rolls 2015–2026) — 693,205 records, loaded Oct 24, 2026, 7:27 AM ET; Dallas County TX (DCAD ownership roll 2026) — 173,688 records, loaded Oct 23, 2026, 8:58 PM ET; Hillsborough County FL (FL DOR 2026 ownership roll + Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026), Miami-Dade County FL (FL DOR 2026 ownership roll) — 294,950 records, loaded Oct 23, 2026, 8:58 PM ET. Still to be looked up for this issuer: NYC ACRIS via NYC Open Data (Real Property Parties 636b-3b5g, Master bnx9-e6tj, Legals 8h5j-fqxa, Document Control Codes 7isb-wh4c) · NYC PLUTO ownership via NYC Open Data (64uk-42ks) · Cook County IL Assessor via Cook County Open Data (Parcel Sales wvhk-k5uv; Parcel Addresses 3723-97qp). Records in other counties, and recorder indexes we do not yet cover, were not searched.

Property records coverage: New York City (ACRIS recorded documents and PLUTO ownership, looked up per issuer when its page is viewed; re-checked when the page is viewed again more than 30 days after the last check); Harris County TX (ownership only, no deed, mortgage or sale records; HCAD ownership rolls 2015–2026); Dallas County TX (ownership only, no deed, mortgage or sale records; DCAD ownership roll 2026); Hillsborough County FL (FL DOR 2026 ownership roll + Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026), Miami-Dade County FL (FL DOR 2026 ownership roll); Cook County IL (assessor ownership and deed/sale records, looked up per issuer when its page is viewed). Recorder indexes (party names on deeds, mortgages and liens) in TX, AZ, NV, CA and WA counties and outside the Clerk index in FL, mortgages and liens outside NYC and Hillsborough County, lis pendens and foreclosure notices everywhere, Los Angeles County CA, Clark County NV, King County WA (loader ready; first load not finished), Cook County IL bulk pass (not finished; per-issuer lookups only so far), New York City bulk pass (not finished; per-issuer lookups only so far), Maricopa County AZ (loader ready; commercial-purpose statement not yet filed), Salt Lake County UT, and all other counties are not covered — not searched. Last refresh by source: Harris County Appraisal District real_acct.txt Oct 24, 2026, 7:27 AM ET; Hillsborough County FL Clerk daily index Oct 23, 2026, 8:59 PM ET; Dallas Central Appraisal District ACCOUNT_INFO.CSV Oct 23, 2026, 8:58 PM ET; Florida DOR NAL roll (Dade 23) Oct 23, 2026, 8:58 PM ET; Florida DOR NAL roll (Hillsborough 39) Oct 23, 2026, 8:54 PM ET. NYC and Cook County are also looked up per issuer when its page is viewed; the most recent such lookup on this site finished Oct 24, 2026, 3:30 AM ET. Parties are named as the recorder's index names them (role suffixes as recorded); no address, account number or trust date is shown for an individual, and individual owners of record (home ownership) are not matched or shown. Items still in human review are not shown.

Offerings (SEC Form D)

Each filing as reported by the issuer, newest first. Open a row for the full plain-English detail. D = original notice, D/A = amendment.

Offerings at a glance — 3 offerings, 4 filings (one row per SEC file number)
File no.Original Form DLatest filingAmendmentsOffered (latest)Sold (latest)Industry (latest)
021-192546Feb 28, 2013 EDGAR ↗Feb 28, 2013 D EDGAR ↗0Indefinite$17,600,000Pharmaceuticals
021-156702Mar 15, 2011 EDGAR ↗Jan 6, 2012 D/A EDGAR ↗1
latest Jan 6, 2012
$49,009,465$39,009,465Pharmaceuticals
021-136458Nov 27, 2009 EDGAR ↗Nov 27, 2009 D EDGAR ↗0Indefinite$2,158,333Pharmaceuticals

Offerings are grouped by SEC file number; rows without a file number (not yet retrieved from EDGAR) are shown as their own offering until the link is fetched.

Feb 28, 2013 D Pharmaceuticals — $17,600,000 sold of Indefinite · 13 investors EDGAR ↗
FilingForm D filed Feb 28, 2013
SEC file no. 021-192546 · accession 0001477598-13-000001
Raise progress$17,600,000 sold of Indefinite offered · Indefinite remaining · first sale Feb 15, 2013
Filing timingDate of first sale: Feb 15, 2013 · Form D filed: Feb 28, 2013 (13 days after first sale)
Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale4,999 days (13.7 years)
Annual amendmentsIssuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET).
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors13 total · issuer reported no non-accredited investors
Exemption claimedRule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c))
Minimum investment accepted$0 as filed (no minimum reported)
Securities offeredDebt; Option, warrant or other right to acquire; Security to be acquired upon exercise
Entity detailsOrganized in DELAWARE · formed 2008 · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryPharmaceuticals
Who is paid to sell itNo sales compensation recipients listed on this filing.
Money to insidersSales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed byGerald Wisler, Chief Executive Officer (Feb 25, 2013)
Market contextNot computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Jan 6, 2012 D/A Pharmaceuticals — $39,009,465 sold of $49,009,465 · 10 investors EDGAR ↗
FilingForm D/A (amendment) filed Jan 6, 2012 · amends 0001477598-11-000002 ↗
SEC file no. 021-156702 · accession 0001477598-12-000002 · filing 2 of 2 in this offering
Raise progress$39,009,465 sold of $49,009,465 offered (80%) · $10,000,000 remaining · first sale Feb 28, 2011
Filing timingDate of first sale: Feb 28, 2011 · Original Form D filed: Mar 15, 2011 (15 days after first sale) · This amendment (Form D/A) filed: Jan 6, 2012
This row is an amendment. Rule: the original Form D is generally due within 15 days after the first sale; the rule sets no deadline measured from an amendment. Dates shown as reported; no conclusion is drawn.
Time since first sale5,717 days (15.7 years)
Annual amendmentsIssuer reported the offering may last more than one year. This filing is an amendment dated Jan 6, 2012. Most recent amendment for this offering in our index: this filing, Jan 6, 2012.
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors10 total · issuer reported no non-accredited investors
Exemption claimedRule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c))
Minimum investment accepted$0 as filed (no minimum reported)
Securities offeredEquity
Entity detailsOrganized in DELAWARE · formed 2008 · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryPharmaceuticals
Who is paid to sell itNo sales compensation recipients listed on this filing.
Money to insidersSales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Issuer's note: Some of the funds will be used as working capital and therefore to pay normal business expenses, such as salaries of officers.
Signed byChristian Schade, Secretary and Treasurer (Jan 5, 2012)
Changes vs previous filing
  • total sold: $33,909,471 (Mar 15, 2011) → $39,009,465 (Jan 6, 2012)
  • total offering: $38,659,480 (Mar 15, 2011) → $49,009,465 (Jan 6, 2012)
  • remaining: $4,750,009 (Mar 15, 2011) → $10,000,000 (Jan 6, 2012)
  • investors: 7 (Mar 15, 2011) → 10 (Jan 6, 2012)
  • related persons added (Jan 6, 2012): Christian Schade, David Mott
  • related persons no longer listed (Jan 6, 2012): Michael Davidson, Douglas Carr
Compared with the D filed Mar 15, 2011 (EDGAR ↗). Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Amendment history as filed; no conclusion is drawn.
Market contextNot computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Mar 15, 2011 D Pharmaceuticals — $33,909,471 sold of $38,659,480 · 7 investors EDGAR ↗
FilingForm D filed Mar 15, 2011
SEC file no. 021-156702 · accession 0001477598-11-000002 · filing 1 of 2 in this offering
Raise progress$33,909,471 sold of $38,659,480 offered (88%) · $4,750,009 remaining · first sale Feb 28, 2011
Filing timingDate of first sale: Feb 28, 2011 · Form D filed: Mar 15, 2011 (15 days after first sale)
Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale5,717 days (15.7 years)
Annual amendmentsIssuer reported the offering may last more than one year. Most recent amendment for this offering in our index: Jan 6, 2012 (EDGAR ↗).
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors7 total · issuer reported no non-accredited investors
Exemption claimedRule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c))
Minimum investment accepted$0 as filed (no minimum reported)
Securities offeredEquity
Entity detailsOrganized in DELAWARE · formed 2008 · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryPharmaceuticals
Who is paid to sell itNo sales compensation recipients listed on this filing.
Money to insidersSales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed byGerald Wisler, Chief Executive Officer (Mar 4, 2011)
Market contextNot computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Nov 27, 2009 D Pharmaceuticals — $2,158,333 sold of Indefinite · 4 investors EDGAR ↗
FilingForm D filed Nov 27, 2009
SEC file no. 021-136458 · accession 0001477598-09-000001
Raise progress$2,158,333 sold of Indefinite offered · Indefinite remaining · first sale Nov 13, 2009
Filing timingDate of first sale: Nov 13, 2009 · Form D filed: Nov 27, 2009 (14 days after first sale)
Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale6,189 days (17.0 years)
Annual amendmentsIssuer reported the offering may last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET).
Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors4 total · issuer reported no non-accredited investors
Exemption claimedRule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c))
Minimum investment accepted$0 as filed (no minimum reported)
Securities offeredEquity
Entity detailsOrganized in DELAWARE · formed 2008 · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing)
As reported by the issuer on Form D (Items 1–2 and 5).
IndustryPharmaceuticals
Who is paid to sell itNo sales compensation recipients listed on this filing.
Money to insidersSales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $400,000 (est.)
Issuer's note: Proceeds will be used for operating expenses, including salaries.
Signed byGerald Wisler, President (Nov 25, 2009)
Market contextNot computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings.
SourceThis filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET
Amendment history — 1 amendment on this page, each compared with the filing before it in the same offering
Amendment filedFile no.Compared withWhat changed (both values as filed)
Jan 6, 2012 EDGAR ↗021-156702Mar 15, 2011 Dtotal sold: $33,909,471 (Mar 15, 2011) → $39,009,465 (Jan 6, 2012) · total offering: $38,659,480 (Mar 15, 2011) → $49,009,465 (Jan 6, 2012) · remaining: $4,750,009 (Mar 15, 2011) → $10,000,000 (Jan 6, 2012) · and 3 more (open the filing above)

Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Values as filed; no conclusion is drawn.

All Form D filings for this CIK on SEC EDGAR ↗. History: 0 new offerings in the last 12 months (new offering = a Form D that is not an amendment) · most recent filing Feb 28, 2013. Industry as reported, by offering: All 3 offerings reported: Pharmaceuticals (2009–2013).

Key people 8

Officers, directors and promoters the issuer itself named on its Form D. Tap a name for every other deal they are on.

NameRelationshipAddress stateOn filings (first → last)Also listed on
BM Bernardus Machielse
person page: Bernardus N. Machielse
Executive OfficerNJFeb 28, 2013
on 1 of 4 filings
listed on the latest filing
1 other issuer
CS Christian SchadeExecutive OfficerNJJan 6, 2012 → Feb 28, 2013
on 2 of 4 filings
listed on the latest filing
—
DM David MottDirectorMDJan 6, 2012 → Feb 28, 2013
on 2 of 4 filings
listed on the latest filing
23 other issuers
GH George HornerDirectorNJMar 15, 2011 → Feb 28, 2013
on 3 of 4 filings
listed on the latest filing
—
GW Gerald WislerExecutive Officer, DirectorNJNov 27, 2009 → Feb 28, 2013
on 4 of 4 filings
listed on the latest filing
—
GS Graziano SeghezziDirectorFrance (as filed: I0)Nov 27, 2009 → Feb 28, 2013
on 4 of 4 filings
listed on the latest filing
1 other issuer
MD Michael DavidsonExecutive OfficerNJMar 15, 2011 → Feb 28, 2013
on 2 of 4 filings
listed on the latest filing
2 other issuers
DC Douglas CarrExecutive OfficerNJNov 27, 2009 → Mar 15, 2011
on 2 of 4 filings
not listed on the latest filing (Feb 28, 2013)
—

Executive officers, directors and promoters as self-reported by the issuer, one row per person. Spellings of the same name (same first and last name, or the same full name that EDGAR split differently into middle and last name) with no conflicting middle initial are shown on one row (none on this issuer); dates and counts come from the filings that list each name. Licensed persons: FINRA BrokerCheck ↗ · SEC IAPD ↗.

Connections

Other issuers listing the same people:

Shared address: this business address appears on no other issuer's filings in our index. As of Oct 23, 2026, 5:45 PM ET.

Other offering types (Regulation A and Regulation Crowdfunding)

Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.

Adviser registration (Form ADV)

Searched SEC Form ADV bulk data (registered + exempt reporting advisers) (24,962 records as of Oct 2, 2026, 8:00 AM ET) — nothing matched Omthera Pharmaceuticals, Inc..

Meta advertising

No Meta Pixel ids or Facebook / Instagram page links on file for Omthera Pharmaceuticals, Inc. as of Oct 24, 2026 — the sponsor website is read for them once it is on file (runs automatically). Meta Ad Library: not searched by PartnerFacts (no API access); a one-tap Ad Library search is under Look further.

Public profiles

Public profiles official links and public statements, each with its source and date

No website or social profile named in Omthera Pharmaceuticals, Inc.'s SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #332,481 of 374,652 in line (1,111 issuers searched so far).

Sources searched for a website: Form C data set (issuer websites as filed), Form ADV data set (Item 1.I of matched advisers) — as of Oct 23, 2026, 11:20 PM ET: none on file for this issuer. The sponsor website, the Internet Archive and GDELT news index are read only once a site is on file; a sponsor's website comes from the issuer's own filings (Form C issuer website; EDGAR company profile), an approved profile claim, Form ADV Item 1.I of its matched adviser, or a web search for the issuer name confirmed on the site's own homepage. We never collect personal or family accounts.

Entity standing: not checked (no official programmatic source for NJ yet).

Export this report as PDF (all source links + data timestamp) · Premium

Request diligence pack (Premium) PartnerFacts asks the sponsor for the standard information pack and delivers it to you labelled "provided by the sponsor".

Corrections log

No corrections have been requested for this page.

Filing-to-filing changes are in Amendment history above.

Facts from public records only, each linked to its source. No ratings, no opinions. Request a correction · Claim this profile · Facts policy

Email me the full report

The complete public-record profile for Omthera Pharmaceuticals, Inc., plus the weekly new-filings list.

What do you want to do?

Only "Connect me" shares your details — with this sponsor, at a flat price we charge them, never tied to whether you invest. "Just researching" shares nothing.

Request a correction

Free. Tell us what's wrong and, if you can, where the correct public record is. Every request is logged with its status (received → under review → fixed / confirmed with source).

Sponsor response

Sponsors may add a sourced explanation next to any fact on this page. Reviewed before publishing; never edits the public record.

Claim this profile (sponsors)

Free. Get the "Claimed by sponsor" chip and a confirmed contact for corrections. Claiming never changes the public-record section.

Look further

One-tap searches on sites we do not index ourselves, with the name pre-filled (New Jersey, NJ). Each opens in a new tab; what you find there is not verified by PartnerFacts.

Social and web

LinkedIn companies ↗Instagram ↗X (Twitter) ↗Facebook ↗YouTube ↗Google ↗Google Images ↗Google News ↗Meta Ad Library ↗

Courts

CourtListener / RECAP (federal) ↗PACER case locator (federal, login) ↗New Jersey state courts — find the court ↗Delaware CourtConnect ↗

Securities regulators

SEC EDGAR full-text search ↗SEC action look-up ↗FINRA BrokerCheck ↗SEC IAPD adviser search ↗

Business registries

New Jersey Secretary of State business search ↗Delaware Secretary of State business search ↗OpenCorporates ↗